U.S. License Holder:
Genzyme
Date of License:
May-07-2001
Last Update:
February-15-2021
FDA-Approved Indications
LEMTRADA (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults..
CAMPATH (alemtuzumab) is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).